Novo says its next-gen obesity drug tops Lilly rival in late-stage study

Novo Nordisk ​said on ‌Monday its ​next-generation ​experimental drug had ⁠achieved ​an estimated ​average weight loss of ​12.4% ​in a late-stage ‌trial ⁠and that it ​was ​superior ⁠to Eli ​Lilly's ​d...

本文内容来自外部来源，点击「继续访问」将跳转到原始发布站点。